Appendix 3X (Initial Director’s Interest Notice) in relation to the appointment of Dr. Hazle effective July 30th, 2018.
View and download Appointment of Director and Appendix 3X.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal